AM

What The Future Holds For Ampliphi Biosciences Corp (OTCMKTS:APHB)?

In the last week of March, there was an increased interest in Ampliphi Biosciences Corp (OTCMKTS:APHB) stock. The exceptional interest was evident in the share volume of almost 8.1 million shares. As a result, the stock price jumped 36.3%. From thereon, the stock reversed its trend and traded subdued in the first week of April. However, on Friday’s trading session, it surged more than 14% to close the session at $0.275.

What’s the trend?

The sudden rise in the stock price and then sudden decline is not something new in the penny stocks. The momentum confuses the investors who are unable to understand what to do in such situations? It becomes an earning opportunity for a swing trader. It was the same case with stock of Ampliphi.

The share price closed around 30 cents in last week of March. It traded near to those levels for another few days. Then the company announced that the European Patent Office granted it the patent for “Bacteriophage-containing Therapeutic Agents.” Despite the positive news, the stock price of Ampliphi reacted negative and closed in red with loss of 1.67%. It accelerated the decline in the first week of April.

The financials

Trading in OTC stocks has always been risky as the financials are not healthy enough to instill confidence in investors. In case of Ampliphi things are at brighter side. As per the quarterly report for period ended September 30, 2014, it reported $9.8 million in cash. It posted total current assets of $10.1 million and total current liabilities stood at $2.5 million.

The revenue in the quarter was zero whereas the loss from operations stood at $5 million. Ampliphi submitted 8-K form stating that its financial results for FY2013 and also for the first three quarter of last year need to be restated. Due to it, it had to delay the annual financial report for FY2014.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.